Objective: To determine whether transcutaneous bilirubin (TcB) from covered skin (TcB-C) during and after discontinuing phototherapy (PHT) is reliable in treating neonatal jaundice.
Introduction
Neonatal hyperbilirubinemia (NHB) occurs in two-thirds of term and late preterm infants. 1 Management of NHB has become more challenging because newborn infants are discharged early and unreliable post-discharge follow-up increases the risk of severe NHB and even bilirubin encephalopathy in these infants. 2 Estimation of jaundice by visual assessment of the skin or sclera is quick, but correlates poorly with total serum bilirubin (TSB) measurement when used in newborn infants with mixed ethnicity and racial backgrounds. Thus, lower thresholds for starting phototherapy (PHT) may be appropriate. 3, 4 Although TSB measurement is reliable, it is a painful and time-consuming procedure. 1 Bilirubin levels before and during PHT are measured as TSB and obtained by heel stick or venous blood draws. Noninvasive transcutaneous bilirubin (TcB) estimation using newer bilirubinometer devices has been shown to be easy, safe, accurate, time-effective and painless. 1 Rubaltelli et al. 5 showed close correlation between TcB measured by BiliCheck, high-performance liquid chromatography and routine laboratory bilirubin measurement independent of race, birth weight and post-natal age. Transcutaneous bilirubin estimation decreases the need for TSB measurement in the management of NHB. 6 Although TcB correlates well with TSB, bilirubin in the skin exposed to PHT is modified and significantly affects TcB. Thus, TcB cannot be used as a surrogate measure of TSB when the infant is receiving PHT. 7, 8 Preliminary studies suggest that by covering the skin during PHT, more accurate approximations of serum bilirubin can be made with TcB measurements. 7 The purpose of this study was to evaluate the accuracy of TcB measurement from the covered and uncovered skin during and after PHT treatment and compare these values with TSB performed at the same time.
Methods

Subjects
This was a prospective observational study conducted at the Newborn Nursery at the UTMB (University of Texas Medical Branch) in Galveston, Texas. The study was approved by the Institutional Review Board of UTMB, and verbal informed consent (assent) obtained from the legal guardians of the infant. We included healthy term newborns who required PHT for the management of NHB. 4 Infants who had congenital viral infections, conjugated hyperbilirubinemia, sepsis, major congenital malformation or any gastrointestinal malformation were excluded from the study.
Protocol
Infants requiring PHT based on the American Academy of Pediatrics guidelines were treated with continuous PHT using standard PHT units (Photo Therapy 4000, Draeger Medical, Telford, PA, USA). Although infants were receiving PHT, their eyes were protected from PHT light by covering both eyes with eye patches (NeoShade Phototherapy Eye Shield, Neotech Products, Valencia, CA, USA). Before starting PHT, a portion of their forehead was covered by a photo-opaque patch 2.5 cm in diameter (BilEclipse Phototherapy Patch, Respironics, Murrysville, PA, USA) to shield the region from PHT exposure. The patch was secured to the skin using liquid adhesive. Transcutaneous bilirubin was measured using the BiliCheck bilirubinometer (Respironics). BiliCheck measures TcB levels using multiwave-length spectral reflectance. All TcB measurements were performed by trained nurses in ambient daylight; the BiliCheck bilirubinometer was calibrated regularly according to the manufacturer's instructions. 1 After starting PHT, TcB was measured every 12 h from PHT exposed (TcB-E) and covered (TcB-C) areas. Six hours after discontinuing PHT, another set of TSB, TcB-E and TcB-C was re-measured.
Total serum bilirubin
Blood samples for TSB were collected by heel stick (200 ml) or venous blood draw. PHT lights were turned off during blood draws and blood samples were protected from light exposure. TSB levels were measured in the laboratory using Vitros 5, 1/FS Chemistry System (Ortho Clinical Diagnostic, Rochester, NY, USA). All blood samples were drawn within 15 min of measuring TcB.
Statistical analysis
A difference in bilirubin measurement technique was determined by repeated-measures ANOVA (analysis of variance) and individual mean contrasts using Bonferroni's t-tests. An arbitrary P-value of <0.05 was selected to indicate statistical significance.
Results
Out of the 54 subjects who assented to participate in the study, only 39 completed the study and were included in the analysis. The mean (±s.d.) gestational age was 39 weeks (±2). Our study population was predominately Hispanic (80%) ( Table 1) .
By repeated-measures ANOVA, the values of the three methods of bilirubin measurement differed at every time point except before starting PHT. Before starting PHT, mean±s.d TSB ¼ 11.5±2.7, TcB-C ¼ 11.1 ± 2.7 and TcB-E ¼ 11.1 ± 2.7 and were not significantly different. However, after 12 h of PHT exposure TcB-E was significantly lower than were TSB (P<0.05) and TcB-C (<0.05). TcB-E was significantly different from TSB and TcB-C at all time points. There were no significant differences between TSB and TcB-C at any time points during PHT and 6 h after stopping PHT ( Table 2 ).
Discussion
In this study, we provide data on TcB measured using BiliCheck from the covered and uncovered skin in term, predominantly Hispanic infants who were receiving PHT for the management of NHB. On the basis of data obtained from this analysis, PHT causes Table 2 Bilirubin measured as serum, transcutaneous (from covered and uncovered skin) before starting phototherapy, during phototherapy and 6 h after discontinuing phototherapy (rebound)
Time (hours)
Age (hours) TSB (mg per 100 ml) TcB-C (mg per 100 ml) TcB-E (mg per 100 ml) Abbreviations: TcB-C, transcutaneous bilirubin from covered skin; TcB-E transcutaneous bilirubin from exposed skin; TSB, total serum bilirubin. *P< 0.05 SB vs TcB-E; w P< 0.05 TcB-C vs TcB-E. Data are shown as mean±s.d. 
or number (%).
Covered transcutaneous bilirubin during PHT R Fonseca et al significant modification of the skin in predominately Hispanic infants within 12 h of PHT exposure. We have shown no differences between TcB-C and TSB, whereas TcB-E was significantly lower than TSB when infants were receiving PHT. Six hours after stopping PHT, TcB-C and TSB were again the same, but TcB-E remained significantly lower than TSB. Engle et al. 9 found that BiliCheck TcB underestimated bilirubin in term Hispanic infants with relatively high TSB (>15 mg per 100 ml). The authors further suggested that the predominant Hispanic population could be responsible for the unreliable results. BiliCheck measures bilirubin by using the entire spectrum of visible light (380 to 760 nm wavelength) and isolates the interfering factors of hemoglobin, melanin pigmentation in the skin and thickness of the skin. 5 The study by Bhutani et al. 1 and our study showed comparable TcB results in Hispanic, nonHispanic Caucasian and African-American infants.
Varvarigou et al. 8 found that TcB measured between 12 and 72 h of life could provide a TcB-based predictive tool that would allow for a painless, noninvasive assessment of NHB in term and late preterm infants. We also used a similar approach of TcB estimation and compared it with TSB before, during and after PHT and showed good agreement in TcB-C and TSB measurements in term infants.
Tan and Dong 10 evaluated the reliability of TcB-C and TcB-E using Minolta-Airshields bilirubin meter (Norcross, CA, USA) on term infants during and after PHT by comparing with control infants who did not receive treatment. They showed poor correlation between TcB-C and TSB in infants who were receiving PHT compared with infants who were not receiving PHT. During PHT, the unexposed skin showed better correlation than did the exposed skin but was poorer than in the control group. After cessation of PHT, recovery of skin color occurred within 24 h. We found no differences between TcB-C and TSB 6 h after discontinuing PHT, whereas TcB-E remained significantly lower than did TSB.
Our study has some limitations. We compared TcB (both TcB-C and TcB-E) with TSB only 6 h after discontinuing PHT. We were unable to determine the time required for TcB-E measurements to become comparable with TSB measurements because most patients were discharged 6 h after the discontinuation of PTH if the rebound TSB was acceptable. As with any point of care test, assessment of the competency of the personnel using transcutaneous bilirubin meter is very important. This should be done on a regular basis by comparing TcB and TSB performed at the same time to determine whether the device needs calibration or to identify operators who require additional training.
During PHT, TcB of the covered skin may be a reliable, painless, simple, quick and cheaper method of monitoring the degree of jaundice in stable infants. Further studies of infants of differing gestational ages are required to determine whether thickness of the skin and bilirubin metabolism alter the reliability TcB.
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